Driving better healthcare through innovation

NEWS & UPDATES

FDA clears Genetic Signatures EasyScreen™ Gastrointestinal Parasite Detection Kit

Genetic Signatures welcomes Allison Rossiter as CEO

Caroline Waldron appointed Chair of Genetic Signatures Board of Directors, effective from 20 November 2024

Anne Lockwood and Dr Jenny Harry appointed as Non-Executive Directors, effective from 1 October 2024

Our Products

Genetic Signatures is transforming molecular diagnostics via streamlined sample processing methods linked to highly multiplexed real-time PCR screening assays.

OUR TECHNOLOGY

Our technology is designed to identify and simplify

The technology not only serves to identify methylation patterns in the
DNA, it can also be used to simplify DNA sequences more generally,
particularly in lower organisms.

Read More
ABOUT US

Transforming Molecular Diagnostics

We focus on the development and commercialisation of our proprietary platform technology, 3base™. Genetic Signatures has released a suite of real-time PCR based products for the routine detection of infectious diseases under the EasyScreen™ brand.

Read More
DNA-helix

We're driving innovation together

Our Products

Genetic Signatures is transforming molecular diagnostics via
streamlined sample processing methods linked to highly multiplexed
real-time PCR screening assays.

The EasyScreen™ Detection Kits simultaneously detect a larger
number of pathogen targets in a shorter time than conventional
methods.

Our Products

Media Centre

Resource Types
  • All media
  • Blog
  • News
  • Events
  • Videos
  • Webinar
  • Publications, Articles & Presentations

Why invest with Genetic Signatures? We're at the forefront of Specialist Molecular Diagnostics.

Find investor resources and ASX announcements here.

Investor Centre